JP Morgan Chase
PGNX

JP Morgan Chase’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

JP Morgan Chase’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-29,048
Closed -$110K – 5908
2020
Q1 		$110K Sell
29,048
-8,369
-22% -$36.1K ﹤0.01% 4488
2019
Q4 		$190K Buy
37,417
+8,915
+31% +$47.2K ﹤0.01% 4693
2019
Q3 		$144K Buy
28,502
+5,141
+22% +$25.6K ﹤0.01% 4771
2019
Q2 		$136K Sell
23,361
-1,451
-6% -$7K ﹤0.01% 4816
2019
Q1 		$116K Sell
24,812
-181,699
-88% -$822K ﹤0.01% 4838
2018
Q4 		$868K Buy
206,511
+186,971
+957% +$952K ﹤0.01% 3836
2018
Q3 		$123K Buy
19,540
+4,479
+30% +$34.4K ﹤0.01% 4877
2018
Q2 		$121K Sell
15,061
-311,501
-95% -$2.38M ﹤0.01% 4768
2018
Q1 		$2.44M Buy
326,562
+237,992
+269% +$1.58M ﹤0.01% 3122
2017
Q4 		$527K Buy
+88,570
New +$538K ﹤0.01% 4040
2017
Q2 		– Sell
-76,925
Closed -$726K – 5361
2017
Q1 		$726K Buy
+76,925
New +$768K ﹤0.01% 3548
2013
Q4 		– Sell
-109,849
Closed -$551K – 4318
2013
Q3 		$551K Sell
109,849
-7,570
-6% -$41.1K ﹤0.01% 3587
2013
Q2 		$524K Buy
+117,419
New +$527K ﹤0.01% 3587

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

JP Morgan Chase's PGNX Position: Q2 2020 in Review

JP Morgan Chase sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 29,048 shares — an estimated $110K sold.

JP Morgan Chase first reported a position in PGNX in Q2 2013 and held it in 13 quarters. The position peaked at $2.44M in Q1 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • JP Morgan Chase reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • JP Morgan Chase sold 29,048 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $110K.
  • JP Morgan Chase first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • JP Morgan Chase's Progenics Pharmaceuticals Inc position peaked at $2.44M in Q1 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.